Fusen Pharmaceutical Company Limited provided earnings guidance for the of the Group for the six months ended June 30, 2020. For the period, the company expects to record an increase in profit attributable to shareholders for the six months ended 30 June 2020 by not less than 40%, as compared with the profit attributable to shareholders of approximately RMB 23.7 million for the six months ended 30 June 2019. The expected increase in net profit of the Group was mainly due to the combined effects of (1) increase in the sales of Shuanghuanglian Oral Solutions, the Group's major products, as a result of increased market demand; (2) contribution from Jiangxi Yongfeng Kangde Pharmaceutical Company Limited, a joint venture of the Group and (3) partly offset by the expenses recognised for the extension of exercise period of the share options for the six months ended 30 June 2020. The Company is still in the process of finalising the consolidated interim results of the Group for the six months ended 30 June 2020. The information contained in this announcement only represents a preliminary assessment based on the unaudited management accounts for the six months ended 30 June 2020 and the information currently available to the Board which has not been reviewed or audited by the auditors of the company. Shareholders and potential investors are advised to read carefully the interim results announcement of the Group for the six months ended 30 June 2020 which is expected to be published before the end of August 2020.